Table 1.
Sample ID | Sex | Age at AML Dx | De novo vs. Secondary | Type of samples | Sample material | FAB | WBC at AML Dx | BM blast count at AML dx | MRC cytogenetics class at AML Dx | Initial Tx | NPM1 at dx | FLT3 ITD at Dx | FLT3 TKD at Dx |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
646 | F | 83.7 | De novo | Diagnosis | PB | M5b | 299 | 70 | Intermediate (abnormal) | Supportive | nd | nd | nd |
90240 | F | 54.2 | De novo | Relapse3 | Peritoneal fluid | M1 | 3 | nd | Adverse | Induction | nd | nd | nd |
80401 | F | 54 | Secondary (MPN) | Diagnosis | PB | M1 | 24 | 60 | Intermediate (abnormal) | Induction | nd | nd | nd |
9682 | F | 76.6 | De novo | Diagnosis | PB | Unclassified | 34 | nd | nd | Supportive | nd | nd | nd |
80529 | F | 29.4 | De novo | Diagnosis | PB | M4 | 21.1 | 60 | Intermediate (normal) | Induction | Positive | Intermediate | Negative |
90185 | F | 35.7 | De novo | Diagnosis | PB | Unclassified | 46 | nd | Intermediate (normal) | Induction | Positive | Intermediate | Negative |
80534 | M | 20.1 | De novo | Relapse1—persistent | PB | M5a | 54 | 95 | Intermediate (normal) | Induction | nd | nd | nd |
90736 | F | 49.9 | De novo | Diagnosis | PB | Unclassified | 41 | nd | nd | Induction | nd | nd | nd |
90707 | M | 59 | De novo | Diagnosis | PB | M4 | 25 | 25 | Intermediate (normal) | Induction | Positive | Negative | Negative |
90784 | F | 61.9 | De novo | Diagnosis | PB | M5a | 59 | 90 | Intermediate (normal) | Positive | High | Negative | |
858 | M | 55.9 | Secondary (MPN) | Diagnosis | PB | M1 | 33 | 70 | Intermediate (normal) | Induction | Positive | Negative | Negative |
100052 | M | 79.2 | Secondary (MDS) | Diagnosis | PB | M4 | 38 | 60 | Adverse | Supportive | nd | nd | nd |
100016 | M | 73.2 | De novo | Diagnosis | PB | M5a | 20 | 80 | Intermediate (normal) | Induction | Negative (K) | Negative (K) | Negative (K) |
100006 | F | 63.3 | De novo | Diagnosis | PB | M5a | 25 | 80 | Intermediate (abnormal) | Induction | nd | nd | nd |
100112 | M | 69.5 | Secondary (MDS) | Persistent disease | PB | nd | 16 | 80 | Intermediate (normal) | Induction | Negative | Negative | Negative |
100116 | F | 65.3 | De novo | Diagnosis | PB | M4 | 46 | nd | nd | Supportive | nd | nd | nd |
100118 | M | 61.8 | De novo | Persistent disease | PB | M1 | 204 | 90 | Intermediate (normal) | Induction | Negative | Intermediate | Negative |
100127 | F | 29.2 | De novo | Relapse1 | PB | Unclassified | 10 | nd | nd | Induction | nd | nd | nd |
100183 | M | 69.8 | De novo | Diagnosis | PB | M5a | 88 | 85 | Intermediate (normal) | Induction | Positive | Negative | Negative |
100207 | M | 71.9 | De novo | Diagnosis | PB | M3 | 62 | nd | Favorable | Induction | nd | nd | nd |
100249 | F | 67.1 | De novo | Diagnosis | PB | Unclassified | 282 | 95 | nd | Induction | Positive | Intermediate | Negative |
100255 | M | 59.6 | De novo | Relapse1 | PB | M4 | 108 | 50 | Intermediate (normal) | Induction | Positive | Negative | Positive |
80014 | M | 52 | Secondary (rads) | Diagnosis | PB | M4Eo | 35.9 | 90 | Favorable | Induction | nd | nd | nd |
90520 | M | 61.7 | De novo | Diagnosis | PB | Unclassified | 103 | 39 | Intermediate (normal) | Induction | Positive | Negative | Positive |
100274 | M | 59.6 | De novo | Relapse1 | PB | M4 | 108 | 50 | Intermediate (normal) | Induction | Positive | Negative | Positive |
100286 | M | 50.5 | De novo | Diagnosis | PB | M1 | 77.2 | 90 | Intermediate (abnormal) | Induction | nd | nd | nd |
90272 | F | 29.2 | De novo | Diagnosis | PB | Unclassified | 10 | nd | nd | Induction | nd | nd | nd |
90517 | M | 61.8 | De novo | Persistent disease | PB | M1 | 204 | 90 | Intermediate (normal) | Induction | Negative | Intermediate | Negative |
90047 | F | 58.3 | De novo | Diagnosis | PB | M4 | 46.9 | 40 | Intermediate (normal) | Induction | Positive | Negative | Negative |
100347 | F | 63.3 | De novo | Diagnosis | PB | M1 | 89.9 | 90 | Intermediate (normal) | Induction | Negative | Negative | Negative |
100454 | M | 62.8 | Secondary (MPN) | Diagnosis | PB | Unclassified | 27 | 50 | Adverse | Supportive | nd | nd | nd |